Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 12/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAP2 | P11137 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173605 | 0.82 | SCN9A (0.46) | SCN9ACYP2C9CYP3A4CYP2D6MAP2 | |
| SCHEMBL21490296 | 0.82 | SCN9A (0.51) | SCN9ACYP2C9CYP3A4CYP2D6MAP2 | |
| SCHEMBL15391364 | 0.78 | SCN9A (0.50) | SCN9ACYP2C9CYP3A4CYP2D6MAP2 | |
| SCHEMBL21490297 | 0.75 | SCN9A (0.50) | SCN9ACYP2C9CYP3A4CYP2D6SCN10A | |
| SCHEMBL351860 | 0.74 | CTNNB1 (0.55) | SCN9ACYP3A4 | |
| SCHEMBL29710969 | 0.74 | CTNNB1 (0.55) | SCN9ACYP3A4 | |
| SCHEMBL29469931 | 0.74 | PTGES2 (0.55) | CYP2C9PTGES2 | |
| SCHEMBL692280 | 0.74 | PTGES2 (0.55) | CYP2C9PTGES2 | |
| Hydrochloric Acid SCHEMBL1267297 | 0.73 | CTNNB1 (0.53) | SCN9ACYP3A4 | |
| Hydrochloric Acid SCHEMBL4379608 | 0.73 | CTNNB1 (0.53) | SCN9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200283403-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2020-09-10 | — | — | US | disclosed |
| US-10647695-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190270721-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2019-09-05 | — | — | US | disclosed |
| US-10329275-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180291000-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2018-10-11 | — | — | US | disclosed |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2013-10-17 | — | — | US | disclosed |
| EP-2611777-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL]AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012031196-A9 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA TM, LLC (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2012031196-A1 | 4- { [ ( PYRIDIN- 3 - YL -METHYL) AMINOCARBONYL] AMINO} BENZENE - SULFONE DERIVATIVES AS NAMPT INHIBITORS FOR THERAPY OF DISEASES SUCH AS CANCER | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647695-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | SCN9A 393/4885CYP2C9 446/4885CYP3A4 1074/4885 |
| US-20200283403-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, HAMP, NQO1 | SCN9A 454/4885CYP2C9 1055/4885CYP3A4 1613/4885 |
| US-20180291000-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, HAMP, NQO1 | SCN9A 454/4885CYP2C9 1055/4885CYP3A4 1613/4885 |
| US-10329275-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNT, NQO1 | SCN9A 393/4885CYP2C9 446/4885CYP3A4 1074/4885 |
| US-20190270721-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, HAMP, NQO1 | SCN9A 454/4885CYP2C9 1055/4885CYP3A4 1613/4885 |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | SCN9A 1075/4885CYP2C9 2180/4885CYP3A4 2444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.